Authors: Guan X et al.
Anesthesiology, March 19, 2026, 10.1097/ALN.0000000000006047
Summary
This multicenter, randomized, phase 3 non-inferiority trial compared remimazolam tosylate—a short-acting benzodiazepine—to propofol for sedation of postoperative mechanically ventilated ICU patients. The study enrolled 211 patients, almost all postoperative, requiring at least 6 hours of sedation with a target RASS of -2 to +1.
Patients were randomized to receive either remimazolam infusion (with weight-based loading and maintenance dosing) or propofol. Sedation success was defined as maintaining the target RASS range for at least 70% of the sedation time without requiring rescue sedation.
The results showed clear non-inferiority of remimazolam compared to propofol. Sedation success rates were very high in both groups—98.1% for remimazolam versus 96.2% for propofol—with a difference well within the predefined non-inferiority margin. Time spent within target sedation range was essentially identical (about 95% in both groups), and the need for rescue sedation was negligible in both arms.
In terms of dosing and control, remimazolam required fewer supplemental doses than propofol, suggesting relatively stable sedation once titrated. The pharmacokinetic profile showed a short terminal half-life of approximately 2 hours, consistent with prior data suggesting rapid offset and predictable recovery.
Safety outcomes were also similar between groups. Adverse events were common—as expected in ICU populations—but largely mild to moderate in both groups. Only one severe adverse event occurred, and that was in the propofol group.
Overall, the study supports remimazolam as an effective and well-tolerated alternative to propofol for short-term ICU sedation in postoperative ventilated patients.
Key Points
- Remimazolam was non-inferior to propofol for ICU sedation in mechanically ventilated postoperative patients.
- Sedation success rates were very high and nearly identical between groups.
- Time in target RASS range (~95%) was equivalent for both drugs.
- Remimazolam required fewer supplemental doses, suggesting stable sedation control.
- Safety profiles were similar, with no signal of increased adverse events.
What You Should Know
This is one of the stronger datasets supporting remimazolam beyond procedural sedation and into ICU use. While it doesn’t dethrone propofol, it gives you a legitimate alternative—especially in patients where hypotension or propofol-related concerns are an issue. The short half-life and benzodiazepine mechanism also raise interesting possibilities for titratability and reversibility (with flumazenil), though delirium implications still need more data. Bottom line: this is a “real option” paper, not just a pharmacology curiosity.
Thank you to Anesthesiology for allowing us to summarize this article.